Upstream Bio Statistics
Total Valuation
Upstream Bio has a market cap or net worth of $1.33 billion. The enterprise value is $954.56 million.
Important Dates
The last earnings date was Wednesday, November 5, 2025, before market open.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Upstream Bio has 54.04 million shares outstanding. The number of shares has increased by 1,624.00% in one year.
| Current Share Class | 54.04M |
| Shares Outstanding | 54.04M |
| Shares Change (YoY) | +1,624.00% |
| Shares Change (QoQ) | +0.30% |
| Owned by Insiders (%) | 0.08% |
| Owned by Institutions (%) | 60.96% |
| Float | 28.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 473.59 |
| Forward PS | 734.23 |
| PB Ratio | 3.50 |
| P/TBV Ratio | 3.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 341.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 32.67, with a Debt / Equity ratio of 0.00.
| Current Ratio | 32.67 |
| Quick Ratio | 31.47 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -40.80% and return on invested capital (ROIC) is -29.15%.
| Return on Equity (ROE) | -40.80% |
| Return on Assets (ROA) | -28.15% |
| Return on Invested Capital (ROIC) | -29.15% |
| Return on Capital Employed (ROCE) | -37.05% |
| Revenue Per Employee | $53,827 |
| Profits Per Employee | -$2.61M |
| Employee Count | 52 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.33% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -5.33% |
| 50-Day Moving Average | 20.49 |
| 200-Day Moving Average | 13.17 |
| Relative Strength Index (RSI) | 60.33 |
| Average Volume (20 Days) | 380,429 |
Short Selling Information
The latest short interest is 2.93 million, so 5.42% of the outstanding shares have been sold short.
| Short Interest | 2.93M |
| Short Previous Month | 3.34M |
| Short % of Shares Out | 5.42% |
| Short % of Float | 10.22% |
| Short Ratio (days to cover) | 7.89 |
Income Statement
In the last 12 months, Upstream Bio had revenue of $2.80 million and -$135.82 million in losses. Loss per share was -$2.62.
| Revenue | 2.80M |
| Gross Profit | 2.80M |
| Operating Income | -140.51M |
| Pretax Income | -122.23M |
| Net Income | -135.82M |
| EBITDA | -140.33M |
| EBIT | -140.51M |
| Loss Per Share | -$2.62 |
Full Income StatementBalance Sheet
The company has $372.43 million in cash and $1.42 million in debt, giving a net cash position of $371.01 million or $6.87 per share.
| Cash & Cash Equivalents | 372.43M |
| Total Debt | 1.42M |
| Net Cash | 371.01M |
| Net Cash Per Share | $6.87 |
| Equity (Book Value) | 378.58M |
| Book Value Per Share | 7.01 |
| Working Capital | 377.11M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$122.26 million and capital expenditures -$296,000, giving a free cash flow of -$122.55 million.
| Operating Cash Flow | -122.26M |
| Capital Expenditures | -296,000 |
| Free Cash Flow | -122.55M |
| FCF Per Share | -$2.27 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -5,020.08% |
| Pretax Margin | -4,366.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Upstream Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,624.00% |
| Shareholder Yield | -1,624.00% |
| Earnings Yield | -10.25% |
| FCF Yield | -9.25% |
Analyst Forecast
The average price target for Upstream Bio is $47.00, which is 91.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $47.00 |
| Price Target Difference | 91.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 44.75% |
| EPS Growth Forecast (5Y) | -10.25% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Upstream Bio has an Altman Z-Score of 31.62 and a Piotroski F-Score of 2.
| Altman Z-Score | 31.62 |
| Piotroski F-Score | 2 |
